In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Private offering by AEterna Zentaris nets $14.1mm

Executive Summary

AEterna Zentaris Inc., which is developing drug candidates for cancer, endocrine diseases, and benign prostatic hyperplasia, netted $14.1mm in a registered direct offering of 11.1mm shares at $1.35 (a 41% premium). Institutional investors also received five-year warrants to buy 4.4mm shares for $1.50. Rodman & Renshaw was the placement agent.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies